Clinical Trials
289 trialsAnalysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
Fox Chase Cancer Center
Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging
Oslo University Hospital
OvAR-Y
Washington University School of Medicine
T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer
University Hospital, Basel, Switzerland
Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT
Lanzhou University Second Hospital
CISTO
University of Washington
Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies.
Istituto Oncologico Veneto IRCCS
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
iCaRe2
University of Nebraska
SR-ULM BC
Duke University
TVNIM-AFU
Association Francaise d'Urologie
CER
Cancer Support Community, Research and Training Institute, Philadelphia
Study on the Effects of Drugs That Modulate the Endocannabinoid System on Spontaneous and Induced Contractility of the Human Detrusor Muscle
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
CISTO2
University of Washington
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Mayo Clinic
Measuring Surgical Recovery After Radical Cystectomy
M.D. Anderson Cancer Center
Tumor Budding and T1 Substaging in Urothelial Bladder Cancer
Assiut University
Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer
Assiut University
BladMetrix
Oslo University Hospital
Determinants of Bladder Cancer Recurrence Study (The DETER Study)
Memorial Sloan Kettering Cancer Center
Detecting CREPT in Urine for Bladder Cancer Diagnosis and Monitoring
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Outcomes of Definitive Radiotherapy for Bladder Cancer
Sohag University
(CLOCS-2)
Imperial College London
METRICS
University of Kansas Medical Center
MicroBlad
University Hospital, Toulouse
VISIOCYT2
Institut Paoli-Calmettes
Bladder Bank (a Prospective Banking Study)
Mayo Clinic
UroDNA
Institut Cancerologie de l'Ouest
GUB-BCR-001
University of Kansas Medical Center
Exploration of HRQOL and Urinary Outcomes Following Partial Cystectomy
Mayo Clinic
MOMENTUM
UMC Utrecht
CONQUER
Aarhus University Hospital
GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy Unit
Aarhus University Hospital
OCCURORTW
Jagiellonian University
The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer
Tianjin Medical University Second Hospital
Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer
Lanzhou University Second Hospital
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Dana-Farber Cancer Institute
WASHOUT
British Urology Researchers in Surgical Training
A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer
Cedars-Sinai Medical Center
A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer
Cedars-Sinai Medical Center
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Cedars-Sinai Medical Center
Predicting BCG Response
Cedars-Sinai Medical Center
A Diagnostic for the Early Detection of Bladder Cancer
Cedars-Sinai Medical Center
Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.
Qilu Hospital of Shandong University
Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.
Qilu Hospital of Shandong University
Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology
Qilu Hospital of Shandong University
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
University of Washington
Genetic Susceptibility to Bladder Cancer
M.D. Anderson Cancer Center
Molecular Analysis Of Bladder Cancer
Lahey Clinic
QSCO
University Hospital, Toulouse